Pharmaceutical manufacturer
Pharmaceutical manufacturer remedies laborious review
Corporation cuts review by 70 percent with OpenText Insight Predict’s continuous active learning
Challenge
- Faced claim of patent infringement
- Started review due to looming deadlines
- Progressed half-way through process before TAR approval
Product(s)
Value
- Leveraged completed work as seed set to train the TAR algorithm
- Reduced remaining review time by 70% with continuous active learning
- Saved nearly $70,000 after accounting for cost of TAR
Contactez OpenText
- Formulaire en ligne
- Bureaux régionaux
- +33 1 47 96 55 41